4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
9.46
+0.01 (0.11%)
At close: Apr 28, 2026, 4:00 PM EDT
9.42
-0.04 (-0.42%)
After-hours: Apr 28, 2026, 4:10 PM EDT
4D Molecular Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for 4D Molecular Therapeutics stock have an average target of 31.71, with a low estimate of 21 and a high estimate of 38. The average target predicts an increase of 235.20% from the current stock price of 9.46.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 30, 2026.
Analyst Ratings
The average analyst rating for 4D Molecular Therapeutics stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 4 | 4 | 4 | 4 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 1 | 1 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 8 | 8 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy Initiates $40 → $21 | Strong Buy | Initiates | $40 → $21 | +121.99% | Mar 30, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $36 | Strong Buy | Reiterates | $36 | +280.55% | Mar 20, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $32 → $35 | Buy | Maintains | $32 → $35 | +269.98% | Mar 19, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $26 | Strong Buy | Maintains | $26 | +174.84% | Mar 19, 2026 |
| Barclays | Barclays | Buy Initiates $33 | Buy | Initiates | $33 | +248.84% | Jan 28, 2026 |
Financial Forecast
Revenue This Year
9.03M
from 85.21M
Decreased by -89.40%
Revenue Next Year
15.38M
from 9.03M
Increased by 70.28%
EPS This Year
-3.99
from -2.42
EPS Next Year
-3.93
from -3.99
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 33.6M | 33.6M | ||||||
| Avg | 9.0M | 15.4M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -60.6% | 271.9% | ||||||
| Avg | -89.4% | 70.3% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.90 | -1.63 | ||||||
| Avg | -3.99 | -3.93 | ||||||
| Low | -5.26 | -5.81 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.